Part II: IPAB revokes Allergan’s patent on eye drugs Ganfort and Combigan
Patent II [ORA/21/2011/PT/KOL] The application was filed against patent No.219504 “Combination of Brimonidine and Timolol” for topical Opthalmic use. The combination is commercially marketed as “Combigan.” The revocation was sought for on various grounds viz., that the Patent was obtained on a false suggestion or representation, that it was obvious, that it did not sufficiently disclose and violated Section 8 of the Patents Act, 1970. The patent was successfully revoked. Applicant According to the applicant, the only advantage of the […]
Part II: IPAB revokes Allergan’s patent on eye drugs Ganfort and Combigan Read More »